Clinical Trials Directory

Trials / Completed

CompletedNCT03181490

Circulating Tumor DNA Methylation Test to Differentiate Benign and Malignant Pulmonary Nodules

Multi-centers Validation of a Circulating Tumor DNA Assay to Differentiate Benign and Malignant Pulmonary Nodules Via Targeted High-throughput DNA Methylation Sequencing

Status
Completed
Phase
Study type
Observational
Enrollment
1,490 (actual)
Sponsor
The First Affiliated Hospital of Guangzhou Medical University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Current state-of-the-art lung cancer early screening utilizes low-dose CT scan to identify lung nodules smaller than 3 cm in diameter. However, it's still a clinical challenge to differentiate between malignant and benign nodules. In previous studies, the investigators had taken the approach of methylation profiling by high throughput bisulfite DNA sequencing in tissue samples to identify specific methylation signatures. The investigators had learned methylation patterns that differentiate malignant vs. benign lesions from tissue samples by in-depth data mining, and then used pattern matching to classify plasma samples. In this study, the investigators are going to validate the efficacy of ctDNA methylation test for diagnosing early lung cancer by comparing results of the pre-surgery ctDNA methylation test with the post-surgery pathology.

Detailed description

This is a prospective, multi-center, observational cohort study and seeks to enroll 1230 participants with pulmonary nodules 5-30mm in diameter. The assay analyzes the ctDNA methylation profiles of lung cancer-specific biomarkers non-invasively using whole blood specimens collected before invasive surgery. The performance characteristics(sensitivity and specificity) of the pre-surgery ctDNA methylation test for detection of early lung cancer is evaluated in comparison to post-surgery pathology.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTCirculating Tumor DNA Methylation TestMethylation profiling by high-throughput bisulfite DNA sequencing in blood sample to differentiate benign and malignant pulmonary nodules

Timeline

Start date
2017-06-08
Primary completion
2019-02-28
Completion
2019-05-31
First posted
2017-06-08
Last updated
2020-04-02

Locations

14 sites across 1 country: China

Source: ClinicalTrials.gov record NCT03181490. Inclusion in this directory is not an endorsement.